AMETEK, Inc.

The claim on this page is specific. The registry scores AMETEK, Inc. at 75.8 out of 100 — a narrow moat on FY2025 filings — and the claim underneath that number is that AMETEK's advantage isn't any single product line. It's the acquisition system itself: a decades-running routine of buying niche instrument and precision-component makers, folding them in, and keeping their economics. Capital allocation scores 80 of 100 (Owner earnings +12.2%/yr, share count flat.). Revenue and EPS trend scores 95. Balance-sheet safety scores 89.

That's the thesis. Now let's try to break it.

Test one: is the growth bought, not earned?

The registry's long arc looks clean — but a serial acquirer's revenue line always looks clean. How much walked in via wire transfer?

The recent acquisition record is dense. AMETEK completed its acquisition of Paragon Medical on December 8, 2023, for approximately $1.9 billion in cash against roughly $500 million in annual sales, per AMETEK's December 2023 announcement. AMETEK's third-quarter 2024 10-Q shows $117.5 million paid in October 2024, net of cash acquired, for Virtek Vision International, a laser-projection maker with about $40 million in annual sales. AMETEK announced Kern Microtechnik, an ultra-precision machining specialist, on February 4, 2025. And on July 21, 2025, AMETEK completed its purchase of FARO Technologies at $44.00 per share — roughly $920 million for a 3D-metrology business with about $340 million in annual sales, per AMETEK's completion release of that date. That's four acquisitions in 19 months.

So does anything grow without a check attached? Recently, yes. In its August 4, 2026 release titled “AMETEK Announces Record Second Quarter 2026 Results and Raises Full Year Guidance,” AMETEK reported record second-quarter sales of $2.04 billion, up 15%, of which 10% was organic growth. Orders were $2.3 billion, up 28%. One quarter isn't a decade. And the organic-versus-acquired split across the full filed financial history isn't establishable from any named source we found — that gap is stated here rather than papered over. Verdict: the recent organic engine is documented; the long-run decomposition isn't.

Test two: does the buying erode the returns?

This is where the thesis takes real damage. Returns on capital is AMETEK's weakest filter, at 54 of 100 — the lowest of the five sub-scores on this page — and the registry's own reading is: Median ROIC 12.6%, above the 12% hurdle in 60% of years. Serial acquisition explains the drag mechanically: every deal loads purchase price onto invested capital. Paying $1.9 billion for Paragon's roughly $500 million in sales — both figures from AMETEK's December 2023 announcement — is about 3.8 times revenue, and capital deployed at that price has to work hard before it clears the hurdle.

14 of 19 measured years clear the 12% return hurdle — most, but not all. That is a passing majority, not a clean sweep. The registry's own tiering currently reads narrow moat.

Test three: what happens if the acquisitions stop?

Two facts frame the financing question here. First, balance-sheet safety scores 89 of 100 (Net debt/EBITDA 0.8x, interest coverage 24x.). But AMETEK's FY2025 Form 10-K says higher borrowings under its revolving credit facility tied to the December 2023 Paragon acquisition increased 2024 interest expense. The score is strong; the acquisition system is not debt-free. Second, pricing power scores 60 (Median gross margin 34.6% over 10y, very stable.) — the acquired businesses, once inside, hold their margin.

But the valuation math is unforgiving on this exact question. The registry's zero-growth baseline — what the shares may support if normalized owner earnings simply hold steady — is $73.49, against a recent price of $241.97. At that price the expectations lens on this page solves for owner earnings growing about 27% a year for 5 years. The capital-allocation note above records what the filed financial history actually delivered; set the two side by side. If acquisitions pause, whatever gap remains has to be closed from somewhere the record hasn't shown.

That test fails. Not the moat — the price.

What survived

The thesis holds, trimmed. The acquisition system is real, named, and recent: Paragon (December 2023), Virtek (October 2024), Kern (announced February 2025), FARO (July 2025), all per AMETEK's own releases and filings. The balance-sheet score is strong, though the financing disclosure above shows the system has used borrowing. Organic growth showed up when checked, at 10% in the quarter reported August 4, 2026. On the return hurdle, 14 of 19 measured years clear 12%, most but not all. The live registry tier remains narrow moat, and the price carries the growth expectation set out above. A narrow moat priced at an implied 27% a year is a fine business and a demanding entry. Those are different findings. Both belong on the page.